Analysis of indications and clinical application population of Venetoclax/Venetoclax (Vekela)

Venetoclax (Venetoclax) is a selective BCL-2 inhibitor that mainly exerts anti-cancer effects by promoting tumor cell apoptosis. Its indications are mainly concentrated in the field of hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and specific high-risk or relapsed and refractory patients. For patients carrying 17p deletions or TP53 mutations, venetoclax shows stronger efficacy, providing a new option for clinical targeted therapy.

In chronic lymphocytic leukemia, venetoclax is mainly used for relapsed or refractory patients who have received previous treatment, as well as first-line elderly patients who are not suitable for chemotherapy. The drug can be used alone or in combination with anti-CD20 antibodies (such as rituximab) to improve response rates and progression-free survival. In acute myeloid leukemia, venetoclax is often combined with low-dose azacitidine or a hypomethylating agent in older or high-risk patients who are not candidates for intensive chemotherapy.

Clinical studies have shown that venetoclax can significantly improve the response rate and complete response rate, especially in patients with specific gene mutations. The drug was generally well tolerated, but attention should be paid to hematological toxicities such as neutropenia, anemia, and thrombocytopenia. In addition, due to the high risk of tumor lysis syndrome, electrolytes and renal function need to be strictly monitored in the early stages of treatment, and the dose must be gradually increased to reduce the risk.

The use of venetoclax needs to be individually adjusted based on the patient's specific condition, age, previous treatment history and comorbidities. Hematological and biochemical indicators should be monitored regularly, and dose adjustment or combined supportive treatment measures should be taken if necessary. Overall, venetoclax provides an efficient targeted treatment option for patients with hematological tumors. It is especially suitable for high-risk, relapsed or refractory patient groups and is an important drug choice for modern precision treatment.

Reference materials:https://www.drugs.com/